Glead Sciences Inc. has agreed to acquire Calistoga Pharmaceuticals Inc. for $375 million, the companies said Tuesday.
Calistoga could earn up to an additional $225 million if certain milestones are achieved.
Seattle-based Calistoga is a privately held biotech company focused on the development of medicines to treat cancer and inflammatory diseases.
No comments:
Post a Comment